Recombinant Human Serum Albumin Market Looks Bullish; Estimated to Grow at 7.2% CAGR from 2021-27

The global Recombinant Human Serum Albumin market was valued at US$ 65 million in 2020 and is expected to reach US$ 105.6 million by the end of 2027, growing at a CAGR of 7.2% during 2021-2027.

Recombinant Human Serum Albumin (Rec. HSA) is animal origin free expressed in E.coli without animal or human derived raw materials. It is also free from other contaminating serum proteins.

Recombinant human serum albumin (rHSA) is genetically engineered and derived from a rice-based expression system. It is a highly purified and completely animal-, virus-, and bacteria-free product that was developed as an alternative to plasma-derived HSA, to which it is structurally equivalent.

Global recombinant human serum albumin key players include Albumedix, Merck, Ventria (InVitria), NCPC, Oryzogen, etc. Global top 2 manufacturers hold a revenue sales market share over 80%. North America is the largest market, with a share about 58%, followed by Europe.

Global Recombinant Human Serum Albumin Market: Drivers and Restrains

The research report has incorporated the analysis of different factors that augment the market’s growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and about each type from 2016 to 2027. This section mentions the volume of production by region from 2016 to 2027. Pricing analysis is included in the report according to each type from the year 2016 to 2027, manufacturer from 2016 to 2021, region from 2016 to 2021, and global price from 2016 to 2027.

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market expert’s opinions have been taken to understand the market better.

Global Recombinant Human Serum Albumin Market: Segment Analysis

The research report includes specific segments by region (country), by manufacturers, by Type and by Application. Each type provides information about the production during the forecast period of 2016 to 2027.

Key Companies profiled in this report are Albumedix, Merck, Ventria (InVitria), NCPC, Oryzogen, HiMedia and more in terms of market share by sales, revenue, average pricing, product type, margins, recent developments etc.

Find more details at:

Segment by Type

  • OsrHSA
  • ScrHSA

Segment by Application

  • Cell Culture Media
  • Medical Supplements
  • Others

Table of Content:

1 Recombinant Human Serum Albumin Market Overview

2 Recombinant Human Serum Albumin Market Competition by Manufacturers

3 Recombinant Human Serum Albumin Retrospective Market Scenario by Region

4 Global Recombinant Human Serum Albumin Historic Market Analysis by Type

5 Global Recombinant Human Serum Albumin Historic Market Analysis by Application

6 Key Companies Profiled

7 Recombinant Human Serum Albumin Manufacturing Cost Analysis

8 Marketing Channel, Distributors and Customers

9 Recombinant Human Serum Albumin Market Dynamics

10 Global Recombinant Human Serum Albumin Market Forecast

11 Research Finding and Conclusion

12 Methodology and Data Source

Media Contact

Company Name: The Market Reports

Contact Person: Shirish Gupta


Phone: +1-631-407-1315